FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:208-209 July 14, 2005 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: A large amount of information suggests that mutations in the kinase domain of epidermal growth factor receptor (EGFR) are critical for the efficacy of EGFR kinase inhibitors.^1,2,3 However, the effect of EGFR mutations on the response to cetuximab has not been directly investigated. Barber et al.⁴ reported the absence of EGFR mutations in colorectal cancers and speculated that EGFR mutations were not required for the response to cetuximab, since it was an efficacious agent against this type of tumor.⁵ We sequenced the kinase domain of EGFR (exons 18, 19, and 21) in tumor samples from 38 patients . . . [Full Text of this Article]

This article has been cited by other articles:

• Vincenzi, B., Santini, D., Galluzzo, S., Russo, A., Fulfaro, F., Silletta, M., Battistoni, F., Rocci, L., Zobel, B. B., Adamo, V., Dicuonzo, G., Tonini, G. (2008). Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome. Clin. Cancer Res. 14: 4219-4224 [Abstract] [Full Text]  
• Peipp, M., Schneider-Merck, T., Dechant, M., Beyer, T., Lammerts van Bueren, J. J., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T. (2008). Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations. J. Immunol. 180: 4338-4345 [Abstract] [Full Text]  
• Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D., Alam, Y., Kreisman, H., Graze, P., Maher, J., Ross, H. J., Ellis, P. M., McNulty, W., Kaplan, E., Pautret, V., Weber, M. R., Shepherd, F. A. (2007). Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer. JCO 25: 5777-5784 [Abstract] [Full Text]  
• Kulke, M. H., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Kwak, E. L., Muzikansky, A., Lawrence, C., Fuchs, C. S. (2007). Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer. JCO 25: 4787-4792 [Abstract] [Full Text]  
• Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., Tan, B. R., Krishnamurthi, S. S., Burris, H. A. III, Poplin, E. A., Hidalgo, M., Baselga, J., Clark, E. A., Mauro, D. J. (2007). Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. JCO 25: 3230-3237 [Abstract] [Full Text]  
• Chau, I, Cunningham, D, Hickish, T, Massey, A, Higgins, L, Osborne, R, Botwood, N, Swaisland, A (2007). Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol 18: 730-737 [Abstract] [Full Text]  
• Steiner, P., Joynes, C., Bassi, R., Wang, S., Tonra, J. R., Hadari, Y. R., Hicklin, D. J. (2007). Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor. Clin. Cancer Res. 13: 1540-1551 [Abstract] [Full Text]  
• Riely, G. J., Politi, K. A., Miller, V. A., Pao, W. (2006). Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clin. Cancer Res. 12: 7232-7241 [Abstract] [Full Text]  
• Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., Tsuchihashi, Z., Mauro, D. J., Rowinsky, E. K. (2006). Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. JCO 24: 4914-4921 [Abstract] [Full Text]  
• Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J. A., Janne, P., Oulid-Aissa, D., Soria, J.-C. (2006). Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study.. Clin. Cancer Res. 12: 6049-6055 [Abstract] [Full Text]  
• Scaltriti, M., Baselga, J. (2006). The epidermal growth factor receptor pathway: a model for targeted therapy.. Clin. Cancer Res. 12: 5268-5272 [Abstract] [Full Text]